{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:11:05Z","timestamp":1785366665929,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.cgh.2007.02.016","type":"journal-article","created":{"date-parts":[[2007,5,7]],"date-time":"2007-05-07T10:23:32Z","timestamp":1178533412000},"page":"729-735.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events"],"prefix":"10.1016","volume":"5","author":[{"given":"Richard A.","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Gartlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory E.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2007.02.016_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/0161-5890(93)90106-L","article-title":"Construction and initial characterization of a mouse-human chimeric anti-TNF antibody","volume":"30","author":"Knight","year":"1993","journal-title":"Mol Immunol"},{"key":"10.1016\/j.cgh.2007.02.016_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions","volume":"7","author":"Scallon","year":"1995","journal-title":"Cytokine"},{"key":"10.1016\/j.cgh.2007.02.016_bib3","series-title":"Drug class review on targeted immune modulators","author":"Gartlehner","year":"2005"},{"key":"10.1016\/j.cgh.2007.02.016_bib4","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2007.02.016_bib5","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib6","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/0959-8049(96)00210-9","article-title":"Rheumatoid arthritis and cancer risk","volume":"32A","author":"Mellemkjaer","year":"1996","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cgh.2007.02.016_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cgh.2007.02.016_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","article-title":"Adverse drug event monitoring at the Food and Drug Administration","volume":"18","author":"Ahmad","year":"2003","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.cgh.2007.02.016_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","article-title":"Perspectives on the use of data mining in pharmaco-vigilance","volume":"28","author":"Almenoff","year":"2005","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System","volume":"53","author":"DuMouchel","year":"1999","journal-title":"The American Statistician"},{"key":"10.1016\/j.cgh.2007.02.016_bib11","series-title":"Empirical Bayes screening for multi-item associations: Seventh ACM SigKDD International Conference on Knowledge Discovery and Data Mining","author":"DuMouchel","year":"2001"},{"key":"10.1016\/j.cgh.2007.02.016_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib13","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","article-title":"TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection","volume":"168","author":"Roach","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2007.02.016_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.cgh.2007.02.016_bib15","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.4049\/jimmunol.165.5.2657","article-title":"Regulation of infection with Histoplasma capsulatum by TNFR1 and -2","volume":"165","author":"Allendoerfer","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.cgh.2007.02.016_bib16","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cgh.2007.02.016_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-230X-3-10","article-title":"A national survey on the patterns of treatment of inflammatory bowel disease in Canada","volume":"3","author":"Hilsden","year":"2003","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.cgh.2007.02.016_bib18","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"Suppl C","key":"10.1016\/j.cgh.2007.02.016_bib20","doi-asserted-by":"crossref","first-page":"29C","DOI":"10.1155\/2000\/698523","article-title":"Long term safety of infliximab","volume":"14","author":"Schaible","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.cgh.2007.02.016_bib21","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib22","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report","volume":"48","author":"Gomez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2007.02.016_bib24","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib25","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/art.20009","article-title":"Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib27","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib28","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.cgh.2007.02.016_bib29","doi-asserted-by":"crossref","first-page":"807","DOI":"10.7326\/0003-4819-138-10-200305200-00008","article-title":"Case reports of heart failure after therapy with a tumor necrosis factor antagonist","volume":"138","author":"Kwon","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2007.02.016_bib30","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.cgh.2007.02.016_bib31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJM200006153422410","article-title":"Thrombotic thrombocytopenic purpura and clopidogrel: a need for new approaches to drug safety","volume":"342","author":"Wood","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2007.02.016_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2007.02.016_bib33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.cgh.2006.05.020","article-title":"Risks and benefits of infliximab for the treatment of Crohn\u2019s disease","volume":"4","author":"Siegel","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2007.02.016_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/pds.995","article-title":"Disproportionality analyses of spontaneous reports","volume":"13","author":"Hennessy","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib35","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/pds.848","article-title":"Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole","volume":"12","author":"Moore","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/pds.849","article-title":"Dealing with uncertainty in drug safety: lessons for the future from sertindole","volume":"12","author":"Waller","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.cgh.2007.02.016_bib38","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/j.1572-0241.2006.00650.x","article-title":"Alosetron: ischemic colitis and serious complications of constipation","volume":"101","author":"Gallo-Torres","year":"2006","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507001875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356507001875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:01:00Z","timestamp":1761541260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356507001875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1542356507001875"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2007.02.016","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2007,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serious Adverse Events With Infliximab: Analysis of Spontaneously Reported Adverse Events","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2007.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 AGA Institute. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}